Hormone Therapy, Breast Cancer Risk and the Collaborative Group on Hormonal Factors in Breast Cancer Article - Revista Brasileira de Ginecologia e Obstetrícia
Revista Brasileira de Ginecologia e Obstetrícia. 2020;42(5):233-234
In August 2019, the safety of menopausal hormone therapy (MHT) returned to the scene again. Once more, its association with breast cancer risk came up, this time in an article published in the prestigious The Lancet (online in August and printed in September/2019). The subject is not new, and authors of the article are not newcomers either. By representing the Collaborative Group on Hormonal Factors in Breast Cancer, they brought a reanalysis of data from studies on the subject published so far.
In summary, they evaluated data from 58 studies, out of which 24 were prospective and 34 were retrospective studies, covering almost 144 thousand postmenopausal women with breast cancer (cases) and close to 425 thousand without the disease (controls). A higher risk for developing breast cancer was found among MHT users. Women taking combined MHT for 1 to 4 years had a relative risk (RR) of 1.60 with a 95% confidence interval (CI) from 1.52 to 1.69, and for estrogen alone, it was observed a RR of 1.17 (95%CI: 1.10-1.26). For more prolonged use (5 to 14 years), RRs were 2.08 and 1.33, respectively.
[…]
Search
Search in:
Search
Search in:
In August 2019, the safety of menopausal hormone therapy (MHT) returned to the scene again. Once more, its association with breast cancer risk came up, this time in an article published in the prestigious The Lancet (online in August and printed in September/2019). The subject is not new, and authors of the article are not newcomers either. By representing the Collaborative Group on Hormonal Factors in Breast Cancer, they brought a reanalysis of data from studies on the subject published so far.
In summary, they evaluated data from 58 studies, out of which 24 were prospective and 34 were retrospective studies, covering almost 144 thousand postmenopausal women with breast cancer (cases) and close to 425 thousand without the disease (controls). A higher risk for developing breast cancer was found among MHT users. Women taking combined MHT for 1 to 4 years had a relative risk (RR) of 1.60 with a 95% confidence interval (CI) from 1.52 to 1.69, and for estrogen alone, it was observed a RR of 1.17 (95%CI: 1.10-1.26). For more prolonged use (5 to 14 years), RRs were 2.08 and 1.33, respectively.
[...]
Comments